2.27
+0.03(+1.34%)
Currency In USD
Address
10835 Road to the Cure
San Diego, CA 92121
United States of America
Phone
858 465 6511
Website
Sector
Healthcare
Industry
Biotechnology
Employees
103
First IPO Date
July 16, 2021
| Name | Title | Pay | Year Born |
| Dr. Jonathan E. Lim M.D. | Co-Founder, Chairman & Chief Executive Officer | 1.1M | 1972 |
| Dr. Michael D. Varney Ph.D. | Chairman of Research & Development, Scientific Advisory Board Member and Director | 89,593 | 1958 |
| Mr. Ebun S. Garner Esq., J.D. | General Counsel & Corporate Secretary | 607,440 | 1972 |
| Dr. Shannon R. Morris M.D., Ph.D. | Chief Medical Officer | 720,640 | 1970 |
| Dr. David M. Chacko M.D. | Chief Financial Officer & Chief Business Officer | 728,816 | 1984 |
| Mr. Brian L. Baker CPA, M.S. | Senior Vice President of Finance | 0 | 1967 |
| Dr. Nik Chetwyn Ph.D. | Chief Operating Officer | 0 | N/A |
| Dr. Lisa Tesvich-Bonora Ph.D. | Chief People Officer | 0 | N/A |
| Ms. Chandra D. Lovejoy M.S. | Chief Regulatory Affairs Officer | 0 | 1971 |
| Dr. Robert Shoemaker Ph.D. | Senior Vice President of Research | 0 | 1981 |
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.